Navigation Links
Alexion Reports Third Quarter 2008 Results
Date:10/23/2008

Continued Strong Uptake of Soliris(R) in U.S. and Europe

Reported Net Sales of $76.5 Million Include Recognition of $5.3 Million for Prior Quarter Shipments

Company Revises Revenue Guidance Upward and Expense Guidance Downward, and Forecasts GAAP Profit in Full Year 2008

Pipeline Progress in Hematology, Oncology, Transplant, Neurology

Third Quarter 2008 Financial Highlights:

-- Soliris(R) (eculizumab) net product sales of $76.5 million in Q3 2008 consisted of $71.2 million in net product sales for shipments that occurred in Q3 plus recognition of $5.3 million from net product sales associated with the decision of certain government payors during Q3 to reimburse for Soliris shipments that occurred in previous quarters.

-- Q3 GAAP net income was $19.7 million, or $0.23 per diluted share, compared to a GAAP net loss of $20.1 million, or $0.27 net loss per share, in Q3 2007.

-- Q3 non-GAAP net income was $25.7 million, or $0.29 per diluted share, compared to a non-GAAP net loss of $14.0 million, or $0.19 net loss per share, in Q3 2007. Q3 2008 non-GAAP net income, excluding the recognition of $5.3 million from prior-quarter shipments would be $20.8 million, or $0.23 per diluted share.

CHESHIRE, Conn., Oct. 23 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company," Nasdaq: ALXN) today announced financial results for the quarter ended September 30, 2008.

Third Quarter 2008 Financial Results:

For the three months ended September 30, 2008, Alexion reported total revenues of $76.5 million from net product sales of Soliris(R) (eculizumab), compared to total revenues of $21.8 million for the same period in 2007. The Q3 2008 revenues consisted of $71.2 million of net product sales from Soliris shipments during Q3, plus recognition of $5.3 million from net product sales associated with the Q3 2008 decision of certain government payors to reimburse for past Soliris shipment
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Alexion to Present at Bear Stearns Healthcare Conference
2. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
3. Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
4. Alexion Reports Fourth Quarter and Full Year 2007 Results
5. Alexion Reports First Quarter 2008 Results
6. Notice of Time Change for Alexions Presentation at the Bank of America 2008 Health Care Conference
7. Alexion to Present at the William Blair 28th Annual Growth Stock Conference
8. Alexion to Present at the Jefferies & Co. 2nd Annual Healthcare Conference
9. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
10. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... CSSi, the leader in patient recruitment solutions ... of the company,s Medical and Clinical Advisory Board ("MCAB") ... William E. Gannon, Jr. to the MCAB. ... The MCAB, with Dr. Gannon,s leadership, will help ... set strategic goals for the advancement and development of ...
(Date:8/19/2014)... ROCKVILLE, Md. , Aug. 19, 2014 /PRNewswire/ ... a biotechnology company developing novel anti-infective biologic and ... infections and diseases, announced today that its novel ... highlighted at the 54 th Interscience Conference ... in Washington D.C. ...
(Date:8/19/2014)... Sales Horizons, a leader in sales ... sales skills training course to help companies develop ... staff spend the majority of their time on client ... or physician practice – providing support and education to ... Sales Horizons believes clinical staff are and should be ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3
... and HONG KONG, Nov. 22, 2011 SuperNova Diagnostics®, Inc., ... health applications, announced that Neil J. Campbell, President and ... Jaffray Healthcare Conference on November 30, 2011 at 10:30 ... Madison Avenue, New York. The presentation will ...
... Ltd today announced that data from Phase 2 studies ... inhibitor pracinostat (SB939) demonstrate promising activity in patients with ... ASH Annual Meeting and Exposition in San Diego, Calif. ... has shown activity in alleviating MF-associated splenomegaly and constitutional ...
... The streaming of real-time information across your field of vision ... a prototype contact lens that could potentially provide the wearer ... today, 22 November, in IOP Publishing,s Journal of Micromechanics ... demonstrated its safety by testing it on live eyes. There ...
Cached Biology Technology:SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City 2S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF) 2S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF) 3Terminator-style info-vision takes step towards reality 2
(Date:8/19/2014)... To improve students, chances of completing introductory biology ... Houston (UH) implemented a comprehensive student success program, ... failure. , Through a grant from the ... of Biology and Biochemistry embarked on a pilot ... for non-majors and "Introductory Biology" for science majors. ...
(Date:8/19/2014)... available in German . ... energy sources. If a large amount of electricity is to ... energy will have to be stored during productive periods so ... capacities are far from adequate for the purpose. Science and ... focus lies on battery systems that used to be too ...
(Date:8/19/2014)... a lemur. It,s not an African Bush Baby or even ... and downright "cool" primate from Southeast Asia. , "It,s really ... Rafe Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. ... furry body; a long tail with a furry tuft at ... look a bit like the disks on the digits of ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... , MADISON - The continued growth of cropland ... agricultural landscapes in the Midwest. A Great Lakes ... simplification is associated with increased crop pest abundance ... by perennial bioenergy crops. While the relationship ...
... LEXINGTON, Ky. − A team of researchers led by ... is making a connection from prehistoric times to the ... create a replacement for oil and coal shale deposits. ... the earth,s energy supply. Tom Niehaus, completing his ...
... Health care laws to protect patients, privacy make ... and test the safety and usability of medical products ... a result, usability errors and hazards may be overlooked, ... issue of Ergonomics in Design, human factors/ergonomics ...
Cached Biology News:Landscape change leads to increased insecticide use in the Midwest 2University of Kentucky-led research could be path to new energy sources 2
... Inhibitors have broad spectrum RNase inhibitory properties, ... the neutral type (1). The 50kDa protein ... to RNases in a 1:1 ratio. The ... Ribonuclease Inhibitor to RNase (e.g., RNase A) ...
...
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
... For nucleofection of optimized cell lines ... including the nucleofection parameters. Nucleofector Kits are ... Device., Different cell lines can be transfected ... viabilities are given in brackets in percent ...
Biology Products: